When it comes to pain management solutions, CBD in sports medicine gives cannabis a league of its own.

Professional athletes are consistently placing high-intensity stress on their bodies, pushing themselves to take their performance to the next level. Along with that constant stress comes inflammation, pain and the potential for injury. Whether bouncing back from a strenuous workout or healing from a serious injury, the recovery time can sideline a competitor from their sport.


For years, professional athletes have unofficially used cannabis to treat post workout inflammation as well as pain from injuries. Now as legalization sweeps the globe, cannabis can finally become a legitimate therapy option in sports medicine. Sports medicine is one of the cannabis industry’s greatest opportunities for innovation as companies develop new products tailored specifically to address the needs of athletes and offer safer alternatives to nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids.

 

What you need to know about Tesla's Battery Day

   
Expert Analysis of Tesla's Battery Day and the impact on Battery Metals Investing.

Much of the focus for now is on cannabidiol (CBD), the non-psychoactive cannabinoid. The market for CBD products is already taking off in the broader medical cannabis market as well as in the nearly US$4 trillion global health and wellness industry.

Signaling the beginning of a shifting paradigm in sports medicine, the World Anti-Doping Agency (WADA) officially removed CBD from its Prohibited Substances List effective January 1, 2018. The change in policy not only opens up opportunities for athletes in need of safe pain management treatments but for cannabis companies as well.

CBD: improved sports recovery and safer pain management

The spreading legalization of cannabis around the world is leading to increased research into the effects of CBD on the human body, providing scientific support for years of positive anecdotal evidence to the therapeutic benefits of cannabis. CBD works in sync with the body’s endocannabinoid system to reduce inflammation and ease pain by binding with CB1 and CB2 receptors, which are found throughout the body, predominantly in central nervous system and immune system tissues. No deaths have ever been reported for CBD product use, and the majority of adverse side effects are considered non-serious.

Fitness fans and professional athletes alike put a lot of stress on their bodies which can result in pain and injury. Too much inflammation to the muscles and joints can hinder recovery and hurt performance. CBD can also help athletes relax and get a good night’s sleep — a critical component to recovery and realizing training gains.

CBD’s anti-inflammatory properties and high-safety profile make it an ideal alternative to NSAIDs like ibuprofen for relieving post-workout muscle soreness. Long-term and chronic use of NSAIDs, once believed to be safe, are now known to cause kidney damage and heart problems, while even at larger doses CBD has minimal side effects. For sports-related injuries, studies have shown that CBD can be an effective substitute for addictive opioids which kill tens of thousands of people each year and ruins countless other lives.

CBD in sports medicine is growing in popularity and product range, including topical creams and gels, capsules, sports drinks, sublingual oils, translingual sprays and transdermal patches. Canadian cannabis life science company Orion Nutraceuticals (CSE:ORI) is working to bring a new cannabis transdermal patch to the market which offers non-invasive, controlled delivery of cannabinoids (including CBD and THC only formulations) into the bloodstream for effective and long-lasting results. The patches can be used for pain management as well as a good night’s sleep.

“We have chosen to prioritize sports medicine as we deem there to be a sizable market for effective, natural treatments with little competition,” Jonathan Fiteni, CEO of Orion Nutraceuticals, told the Investing News Network (INN). “Research in the area has shown that cannabis derived products can treat athletes for everything from inflammation to concussions.”

Research into cannabis pills for concussions — traumatic brain injuries prevalent in contact sports leagues like the NFL —  are indeed showing signs of success in improving cognitive function. Researchers at the University of Miami Miller School of Medicine are carrying out a five-year study to examine the effects of combining CBD with an anesthetic for the treatment of traumatic brain injury and concussion. Early results have strengthened the researchers’ belief that the combo could “reduce post-injury brain cell inflammation, headache, pain and other symptoms associated with concussion,” stated a recent press release.

While medical researchers continue to study the potential benefits of CBD for the management of pain, inflammation and sleep, many current and former athletes are already choosing cannabis over opioids and traditional sleep aids. Professional cyclist Andrew Talansky told Outside magazine that when he strained a hip flexor in the fall of 2017, he passed over the ibuprofen for CBD to treat his inflammation. “I took it for a couple of weeks, and there was a noticeable difference immediately,” Talansky said. “And it wasn’t just that my hip was feeling better. I was less anxious, and I was sleeping better.”

Emerging market players for CBD in sports medicine

The market for CBD in sports medicine is still emerging, so we don’t have any definitive numbers on the projected size of this sector. However, the total global CBD market is expected to hit US$22 billion by 2022 while the broader medical cannabis market is forecast to reach an estimated US$55.8 billion by 2025.

Currently, many major sporting leagues don’t allow players to use cannabis or CBD products, medical or otherwise. Yet some may be coming around to the idea as more and more current and former players go to bat for revised policies that acknowledge the therapeutic value of CBD in sports medicine and the potential to combat the rising opioid epidemic.

Ice Cube’s BIG3 — a three on three basketball league with rosters made up of retired NBA players like Nate Robinson and Jermaine O’Neal — is in Cube’s own words “ahead of the game” with the June 2018 announcement that it would allow players to use CBD. “This is a no-brainer decision,” BIG3 league co-founder Jeff Kwatinetz said told CBS Sports. “This is a medical decision. It is a medical and a humane decision. To not allow athletes to use CBD and instead to force them to use opioids is irresponsible…It reflects an attitude of not caring about player health.”

There are signs that the major sports leagues are willing to rethink their cannabis policies. The NBA, NHL and the NFL have publicly said they are studying agreements that would allow players to use cannabis in pain management.

 

What you need to know about Tesla's Battery Day

   
Expert Analysis of Tesla's Battery Day and the impact on Battery Metals Investing.

Although this may seem like a small step forward, many in the industry have confidence that major sports leagues will eventually play ball. “There are certain industries where you find a battle between old beliefs and progressive decision making. Before we knew the health benefits of plant-based medicine, much of society’s initial reaction was to treat it like a drug worse than alcohol. Fast forward to today, and the evangelist group for marijuana adoption is growing,” former collegiate track runner and co-founder of cannabis business holding company Orthogonal Collective, AJ Agrawal told Forbes.

The market for CBD in sports medicine is still in its early-stages, which represents blue sky potential for early entrants. Understanding this window of opportunity to, as Ice Cube calls it, get ahead of the game, Orion Nutraceuticals is stacking the roster of its advisory board with athletes, sports therapists, alternative medicine advocates, CBD researchers and sports product marketing professionals.

A few other cannabis companies developing CBD products for this emerging market are Isodiol International Inc. (CSE:ISOL,OTC:ISOLF,FSE:LB6A.F), which has developed a line of CBD performance products aimed at the fitness industry and athletes; and Phivida Holdings Inc. (CSE:VIDA,OTCQX:PHVAF), which has recently said the WADA decision will enable the company to expand its business by offering CBD products to the sports medicine market and competitive athletes.

Takeaway

CBD in sports medicine represents a major turnover in how athletes both recover from training stress and manage pain. The ability to improve recovery through safe and effective pain management, inflammation relief and a better night’s sleep not only offers athletes great potential to improve their athletic performance — it has the potential to dramatically reduce the dangerous consumption of NSAIDS, opioids and prescription sleep aids, a huge win for today’s athletes.

This article was written according to INN editorial standards to educate investors.

Centurion to acquire a Disruptive Water-Soluble Cannabinoid Technology Platform Delivering Rapid Onset, Increased Bioavailability, Premium Taste Profiles and Highly Competitive Cost Structure

Centurion Minerals Ltd. (TSXV: CTN) (FSE: XJCB) (“Centurion” or the “Company”) is pleased to announce that it has entered into an Amalgamation Agreement dated February 17, 2021 (the “Agreement”), with HAI Beverages Inc. (“HAI”), whereby Centurion will acquire 100% of the outstanding shares and assets of a wholly-owned subsidiary of HAI (“NewHAI) in exchange for common shares of Centurion (the “Acquisition” or “Transaction”). NewHAI holds all material assets of HAI and the Acquisition will constitute a reverse take-over (“RTO”) of the Company.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today its participation in the following investor conferences:

  • Needham 2nd Annual Virtual Cannabis Conference – March 3 rd , 2021 – Management will participate in virtual one-on-one meetings.
  • 33rd Annual Roth Conference – March 15 th -17 th , 2021 – Charlie Bachtell, CEO and Co-Founder, will participate in a Fireside Chat and management will later participate in virtual one-on-one meetings on April 7 th .
  • Stifel Multi-Sector Conference – April 21 st , 2021 – Management will participate in virtual one-on-one meetings.

About Cresco Labs

Keep reading... Show less

Green Thumb Industries, a leading cannabis consumer packaged goods company and owner of Rise™ Dispensaries, is expanding key partnerships and creating scholarships earmarked for those from communities most impacted by the war on drugs as part of its corporate social responsibility program. The scholarships will be granted to a total of four students for programs at the Cleveland School of Cannabis in Ohio and Olive-Harvey College in Illinois. Additionally, Green Thumb will continue its support of Cabrini Green Legal Aid and partner with the North Lawndale Employment Network in Chicago as part of ongoing collaborations that include financial support, volunteerism and awareness initiatives.

Building on the foundation of Green Thumb’s LEAP initiative, which provided pro-bono support for social equity license applicants in Illinois and which will soon offer business incubator resources to newly awarded social equity entrepreneurs, these impactful partnerships mark a critical next step in prioritizing diversity, equity, and inclusion in the cannabis industry.

Keep reading... Show less

All five flavours of the Company’s KOIOS™ nootropic beverage product are now being carried by Jensen’s, a regional supermarket chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. This placement of KOIOS™ follows several other recent placements of the Company’s beverage products in regional supermarket chains across the United States as part of a strategy to passively build market share in specific geographical areas.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that the full range of five flavours of its KOIOS ™ nootropic beverages can now be purchased at all grocery stores operated by Jensen’s Foods (“Jensen’s”), a long-established family-owned grocery chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. In a press release dated February 19, 2021 the Company announced another chain-wide placement of KOIOS ™ nootropic beverages on the west coast of the United States with Market of Choice in Oregon. With this placement of KOIOS ™ in Jensen’s supermarkets, the Company’s beverage products are now carried in approximately 180 retail stores on the west coast, out of a total of more than 4,000 retail stores nationwide.

Keep reading... Show less

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less